COVID-19 Registry at San Matteo (SMACORE) - patient-matching observational registry
Official title: SMAtteo COvid19 REgistry (SMACORE)
Run by Fondazione IRCCS Policlinico San Matteo di Pavia · NCT07597876 · Data updated 2026-11-12
This registry tests how COVID-19 patients are being treated and progress across San Matteo in Pavia to understand patterns and outcomes.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 1000 (estimated) |
| Sponsor | Fondazione IRCCS Policlinico San Matteo di Pavia Academic / other |
| Locations | 1 site (Pavia) |
| Status | Recruiting |
| Started | May 20, 2020 |
| Main results expected | January 20, 2023 |
| Study ends | January 2028 |
| Registry record updated | May 19, 2026 |
| Trial ID | NCT07597876 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are individuals diagnosed with COVID-19 who receive care at Fondazione IRCCS Policlinico San Matteo in Pavia.
✕Probably not a fit
Patients not receiving care at the San Matteo center or without a confirmed COVID-19 diagnosis may not contribute to the registry insights.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
SMACORE is an observational registry led by Fondazione IRCCS Policlinico San Matteo in Pavia, Italy, collecting data on people diagnosed with COVID-19. The project aims to document clinical characteristics, treatments, and outcomes to describe how the disease affected patients in the region. It does not assign any intervention or randomize participants; data are observed passively from routine care. The registry helps researchers analyze trends and identify factors associated with different outcomes. No formal hypotheses or endpoints are specified in the available summary.
Why it matters
Potential benefit: If successful, the registry could help clinicians and policymakers understand COVID-19 patterns and inform care decisions.
How similar studies have gone: Other regional COVID-19 registries have shown value in documenting care patterns and outcomes, supporting broader data-driven insights.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * diagnosis of Covid-19 Exclusion Criteria: \-
Where it's running
-
Fondazione IRCCS Policlinico San Matteo
Pavia, Italy Recruiting
Study contacts
- Study coordinator: Raffaele Bruno
- Email: r.bruno@smatteo.pv.it
- Phone: 0382501080
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) in Adults
This study tests and compares the immune responses and tolerability of the latest COVID-19 vaccines from Novavax and Pfizer/BioNTech in adults at risk for severe COVID-19.
-
Omicron-based COVID-19 vaccine with Matrix-M given as a single dose in older adults and high-risk individuals
A single-dose Omicron-subvariant vaccine with Matrix-M is tested to see if it is safe and can induce an immune response in adults 65+ and in younger adults with conditions that raise the risk of severe COVID-19, who were previously vaccinated.
-
Secutrelvir for nonhospitalized COVID-19 in teens and adults
This study tests whether secutrelvir can help nonhospitalized people with COVID-19 see faster symptom relief compared with a placebo.
-
Virological Monitoring of Seasonal Respiratory Infections in France
This project tests how often common respiratory viruses show up in patients seen by primary care doctors in metropolitan France during the fall and winter.
-
MDX2301 in healthy adults and adults at higher risk for severe COVID-19
This study will try single and repeat doses of MDX2301 given by IV, IM, or SC to see if they are safe and trigger neutralizing activity in healthy adults and adults at higher risk for severe COVID-19.
-
Optimizing antiviral treatment for immunocompromised people with COVID-19
This trial will test whether adding remdesivir to Paxlovid or extending Paxlovid from 5 to 10 days helps immunocompromised people with asymptomatic or mild-to-moderate COVID-19.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.